220 related articles for article (PubMed ID: 22450391)
1. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
Kiltz U; Heldmann F; Baraliakos X; Braun J
Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
[TBL] [Abstract][Full Text] [Related]
2. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
Haibel H; Sieper J
Curr Opin Rheumatol; 2010 Jul; 22(4):388-92. PubMed ID: 20473176
[TBL] [Abstract][Full Text] [Related]
3. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
[TBL] [Abstract][Full Text] [Related]
4. The treatment of ankylosing spondylitis.
Scalapino KJ; Davis JC
Clin Exp Med; 2003 Feb; 2(4):159-65. PubMed ID: 12624705
[TBL] [Abstract][Full Text] [Related]
5. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
[TBL] [Abstract][Full Text] [Related]
6. Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors.
Her M; Kavanaugh A
Curr Opin Rheumatol; 2013 Jul; 25(4):455-9. PubMed ID: 23680779
[TBL] [Abstract][Full Text] [Related]
7. [Axial spondyloarthritis and ankylosing spondylitis].
Nordström D; Kauppi M
Duodecim; 2010; 126(12):1467-74. PubMed ID: 20617750
[TBL] [Abstract][Full Text] [Related]
8. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
Sieper J; Rudwaleit M
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
[TBL] [Abstract][Full Text] [Related]
9. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
Brandt J; Sieper J; Braun J
Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
Tse SM; Burgos-Vargas R; Laxer RM
Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
[TBL] [Abstract][Full Text] [Related]
12. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
[TBL] [Abstract][Full Text] [Related]
13. New treatment targets in ankylosing spondylitis and other spondyloarthritides.
Song IH; Poddubnyy D
Curr Opin Rheumatol; 2011 Jul; 23(4):346-51. PubMed ID: 21508843
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice.
Elewaut D; Matucci-Cerinic M
Rheumatology (Oxford); 2009 Sep; 48(9):1029-35. PubMed ID: 19561158
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
Song IH; Maksymowych WP
Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
[TBL] [Abstract][Full Text] [Related]
16. Recognition and treatment of juvenile-onset spondyloarthritis.
Gensler L; Davis JC
Curr Opin Rheumatol; 2006 Sep; 18(5):507-11. PubMed ID: 16896291
[TBL] [Abstract][Full Text] [Related]
17. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.
Song IH; Heldmann F; Rudwaleit M; Haibel H; Weiss A; Braun J; Sieper J
Ann Rheum Dis; 2011 Jun; 70(6):1108-10. PubMed ID: 21415053
[TBL] [Abstract][Full Text] [Related]
18. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
19. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
Smith N; Gadsby K; Butt S; Deighton C
Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
[No Abstract] [Full Text] [Related]
20. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]